Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab

Patients with salivary duct cancer (SDC) and HER2 overexpression could receive trastuzumab in combination with chemotherapy for metastatic disease. No standard treatment exists for patients with HER2-positive metastatic SDC after progression. We report an excellent patient response to second-line tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Corrêa, Tatiana Strava, Matos, Gustavo Duarte Ramos, Segura, Marcos, dos Anjos, Carlos Henrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981674/
https://www.ncbi.nlm.nih.gov/pubmed/29867432
http://dx.doi.org/10.1159/000488669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981674/
https://www.ncbi.nlm.nih.gov/pubmed/29867432
http://dx.doi.org/10.1159/000488669

Ejemplares similares